Choose a language and wait for the translated text.
Shots:
The EMA has validated 2 MAAs from Daiichi Sankyo for oral, single-pill triple combinations of bempedoic acid + ezetimibe with either atorvastatin or rosuvastatin to treat adults with primary hypercholesterolemia or mixed dyslipidemia
The therapies aim to reduce LDL-C levels & CV risk; multiple statin dose options of each combination are intended to offer flexibility in tailoring treatment to individual patient needs
If approved, they could be the first oral single-pill triple combinations for lipid-lowering in the EU, aiming to reduce pill burden & support medication adherence in patients requiring multiple lipid-lowering agents
Ref: Business Wire | Image: Daiichi Sankyo | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post The EMA Validates Daiichi Sankyo’s MAAs for Single-Pill Triple Combinations of Bempedoic Acid + Ezetimibe + Statin for Hypercholesterolemia appeared first on PharmaShots.
The EMA Validates Daiichi Sankyo’s MAAs for Single-Pill Triple Combinations of Bempedoic Acid + Ezetimibe + Statin for Hypercholesterolemia | PharmaVoice
